Xponance Inc. trimmed its holdings in Revvity, Inc. (NYSE:RVTY – Free Report) by 2.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,124 shares of the company’s stock after selling 398 shares during the period. Xponance Inc.’s holdings in Revvity were worth $1,796,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently made changes to their positions in the business. Czech National Bank raised its stake in Revvity by 0.5% during the 1st quarter. Czech National Bank now owns 21,713 shares of the company’s stock valued at $2,280,000 after purchasing an additional 99 shares during the period. Garrison Asset Management LLC grew its holdings in Revvity by 0.5% during the 2nd quarter. Garrison Asset Management LLC now owns 21,328 shares of the company’s stock valued at $2,236,000 after buying an additional 103 shares in the last quarter. TriaGen Wealth Management LLC raised its position in shares of Revvity by 2.3% during the second quarter. TriaGen Wealth Management LLC now owns 4,767 shares of the company’s stock valued at $500,000 after buying an additional 107 shares during the last quarter. Guinness Asset Management LTD lifted its holdings in shares of Revvity by 3.3% in the second quarter. Guinness Asset Management LTD now owns 3,587 shares of the company’s stock worth $376,000 after buying an additional 116 shares in the last quarter. Finally, Inspire Investing LLC boosted its position in shares of Revvity by 2.9% during the first quarter. Inspire Investing LLC now owns 4,190 shares of the company’s stock worth $440,000 after acquiring an additional 117 shares during the last quarter. Institutional investors own 86.65% of the company’s stock.
Insider Buying and Selling at Revvity
In other news, insider Joel S. Goldberg sold 3,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $117.86, for a total transaction of $412,510.00. Following the transaction, the insider now directly owns 33,400 shares of the company’s stock, valued at $3,936,524. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.60% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on RVTY
Revvity Trading Up 3.5 %
RVTY opened at $126.34 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.27. The stock’s 50 day moving average price is $119.75 and its 200-day moving average price is $110.91. Revvity, Inc. has a one year low of $79.50 and a one year high of $128.15. The stock has a market cap of $15.59 billion, a price-to-earnings ratio of 104.41, a P/E/G ratio of 2.90 and a beta of 1.05.
Revvity (NYSE:RVTY – Get Free Report) last announced its quarterly earnings data on Monday, July 29th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.12 by $0.10. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The company had revenue of $691.70 million for the quarter, compared to the consensus estimate of $690.33 million. During the same quarter in the prior year, the company posted $1.21 EPS. Revvity’s quarterly revenue was down 2.5% on a year-over-year basis. On average, equities analysts forecast that Revvity, Inc. will post 4.75 EPS for the current year.
Revvity Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 18th will be issued a dividend of $0.07 per share. The ex-dividend date is Friday, October 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.22%. Revvity’s payout ratio is 23.14%.
Revvity Profile
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Featured Articles
- Five stocks we like better than Revvity
- Investing in Construction Stocks
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Investing in Commodities: What Are They? How to Invest in Them
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity, Inc. (NYSE:RVTY – Free Report).
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.